The inhibition of TNKS1/2 (Solberg et al., 2018) and an inactive Wnt/β-catenin signaling pathway (Mook et al., 2017; Nusse and Clevers, 2017) are attractive for treatment of several types of cancer. Here, TNKS is linked to cancer.